GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Net Income Including Noncontrolling Interests

Prostatype Genomics AB (OSTO:PROGEN) Net Income Including Noncontrolling Interests : kr-34.04 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Prostatype Genomics AB's Net Income Including Noncontrolling Interests for the three months ended in Jun. 2023 was kr-10.09 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 was kr-34.04 Mil.

Prostatype Genomics AB Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Prostatype Genomics AB's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Net Income Including Noncontrolling Interests Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
-9.32 -8.55 -15.63 -29.09 -41.44

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.98 -8.16 -7.81 -10.09 -

Prostatype Genomics AB Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-34.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XSAT:SPERM OSTO:IMMNOV XSAT:GEAN XSAT:ALPH XSAT:CALMA B NGM:ATANA OSTO:AROC TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX WAT
Traded in Other Exchanges
PGO:Germany
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Website
https://www.prostatypegenomics.com
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines